EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study

Murad Guliyev, Gülin Alkan Şen, İlkay Gültürk, Nargiz Majidova, Goncagül Akdağ, Ali Ahadzade, Hande Turna, Nebi Serkan Demirci

Breast Cancer Research and Treatment · 2024-06 · 205 (3) · 633-640

DOI: 10.1007/s10549-024-07291-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 25.03.2024. Verfasst von Murad Guliyev und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, Istanbul, Turkey. drmu…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul University Cerrahpaşa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Endocrine therapy (ET) in combination with CDK 4/6 inhibitors (CDK 4/6i) is the standard treatment modality for hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (mBC). There is uncertainty about the prognostic and predictive value of HER2-low status and whether HER2-low BC is an individual biologic subtype. In this study, we aimed to investigate the prognostic effect of HER2 expression status on survival in mBC patients treated with first-line ET plus CDK 4/6i.

Methods

This multicenter retrospective study included patients with HR + /HER2-negative mBC cancer who were treated with first-line CDK 4/6i in combination with ET from January 2016 to March 2023. Patients were divided into two groups (HER2-low and zero), and survival and safety analyses were performed.

Results

A total of 201 patients were included in this study; of these, 73 (36.3%) had HER2-low disease and 128 (63.7%) had HER2-zero. There were 135 patients (67.2%) treated with ribociclib and 66 (32.8%) with palbociclib. Most of the patients (75.1%) received aromatase inhibitors as combination-endocrine therapy. Baseline characteristics were similar between the two groups. The median follow-up was 19.1 months (range: 2.5–78.4). The most common side effect was neutropenia (22.4%). The frequency of grade 3–4 toxicity was similar between the HER2-zero and low patients (32% vs 31.5%; p = 0.939). Visceral metastases were present in 44.8% of patients. Between the HER2-low and zero groups, median PFS (25.2 vs 22.6 months, p = 0.972) and OS (not reached vs 37.5 months, p = 0.707) showed no statistically significant differences.

Conclusion

The prognostic value of HER2-low status remains controversial. Our study showed no significant effect of HER2 low expression on survival in patients receiving CDK 4/6i plus ET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsHumansFemaleRetrospective StudiesMiddle AgedAgedAdultPrognosisPyridinesPiperazinesPurinesNeoplasm MetastasisAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overBiomarkers, Tumor

Stichwörter der Autor:innen

Breast cancerHER2-lowPalbociclibRibociclib

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsPyridinesPiperazinesPurinesAminopyridinesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, Istanbul, Turkey. drmuradguliyev@gmail.com.
  • Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
  • Division of Medical Oncology, Department of Internal Medicine, Marmara University, Istanbul, Turkey.
  • Department of Medical Oncology, Kartal Dr. Lütf Kirdar City Hospital, Health Science University, Istanbul, Turkey.
  • Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, Istanbul, Turkey.

Förderung

  • Istanbul University Cerrahpaşa

Zitieren

APA

Guliyev, M., Şen, G. A., Gültürk, İ., Majidova, N., Akdağ, G., Ahadzade, A., Turna, H., & Demirci, N. S. (2024). The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study. Breast Cancer Research and Treatment, 205(3), 633-640. https://doi.org/10.1007/s10549-024-07291-0

Vancouver

Guliyev M, Şen GA, Gültürk İ, Majidova N, Akdağ G, Ahadzade A, et al. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study. Breast Cancer Research and Treatment. 2024;205(3):633-640. doi:10.1007/s10549-024-07291-0

BibTeX
@article{Guliyev2024,
  author = {Guliyev, Murad and Şen, Gülin Alkan and Gültürk, İlkay and Majidova, Nargiz and Akdağ, Goncagül and Ahadzade, Ali and Turna, Hande and Demirci, Nebi Serkan},
  title = {The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  volume = {205},
  number = {3},
  pages = {633--640},
  doi = {10.1007/s10549-024-07291-0}
}
Kostenlos starten →